Columbia Care Sees Consensus Price Target Rise To $14.70

On August 12, Columbia Care Inc. (CSE: CCHW) reported its second-quarter financial results, wherein the company announced record revenues of $109.7 million, up 19% sequentially, with a gross margin of 43%. Gross profits rose 23.6% to $43.3 million, while Adjusted EBITDA came in at $16.4%, up 58% sequentially, and an EBITDA margin of 15%. The company reaffirmed its full year 2021 guidance of $500-$530 million in revenue and an Adjusted EBITDA of $95-$105 million.

Analysts made a few changes to their 12-month price target, raising the average consensus to $14.70 from $13.77 before the earnings. Columbia Care has 12 analysts covering the stock with 4 having strong buy ratings, 7 have buy ratings and a single analyst has a hold rating. The street high sits at $19 while the lowest comes in at $12.

Canaccord reiterated their buy rating and $15 price target on Columbia Care, saying that the company reported solid top-line growth and the company remains its top pick in their cannabis coverage.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Columbia Care generally came in line with Canaccord estimates, barely missing their revenue and Adjusted EBITDA expectations. Canaccord says that the revenue growth was boosted by a partial inclusion of Greem Leaf Medical. While Columbia Care reported California, Colorado, Massachusetts, Ohio, and Pennsylvania as its top 5 markets, Canaccord says its other operations in the states of Flordia, Arizona (+23), New Jersey (+20%), and Illinois (+15%) saw great growth.

Columbia Care saw its dispensary count increase to 77 retail locations with further locations in various stages of completion. The company also is adding to its Colorado exposure by acquiring Medicine Man for $42 million.

Below you can see Canaccord’s updated 2021 and 2022 estimates.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Seabridge Loses KSM’s Substantially Started Status

This Gold Giant Got Crushed… Now It’s the Cheapest Major | Kinross Gold’s Q3 Earnings

Why I’m Still Bullish on Gold Below $3,900 | Wes Hanson – Thunder Gold

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Farmers Edge: Canaccord, National Bank Initiate With $25 Price Target

Early this month Farmers Edge inc (TSX: FDGE) completed their $125 million IPO on the...

Friday, March 26, 2021, 11:41:00 AM

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM

Stifel Downgrades Aurora Cannabis Price Target To $3.60 Based On Liquidation Analysis

This morning, Stifel downgraded their 12-month price target on Aurora Cannabis (TSX: ACB) (NYSE: ACB)...

Wednesday, October 28, 2020, 10:59:00 AM

BMO Lowers Revenue Forecast For OceanaGold Following COVID Outbreak

OceanaGold Corp (TSX: OGC) provided a corporate update to their investors on August 27. Included...

Sunday, August 30, 2020, 01:43:00 PM

Canaccord: IAMGOLD Has “Few Desirable Options To Plug Funding Gap”

On May 3, IAMGOLD Corporation (TSX: IMG) reported its first quarter results for 2022. The...

Thursday, May 5, 2022, 02:24:00 PM